RADNOR, Pa., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) ("AtaiBeckley” or "Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by ...
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C ...
Front Cover -- Designing Science Presentations -- Designing Science Presentations -- Copyright -- Contents -- About the author -- Acknowledgments -- 1 -- Using design ...
A prospective natural history study for GM1 and GM2: 24-month data from the PRONTO study – Poster number 132, providing insights into disease progression in GM1 and GM2 gangliosidoses. A Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results